DoubleLine ETF Adviser’s AbbVie ABBV Stock Holding History

DoubleLine ETF Adviser’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.93M	Sell	19,587 -2,217	-10%	-$477K	2.04%	9
2026 Q1	$4.74M	Buy	+21,804	New	+$4.84M	1.8%	10

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DoubleLine ETF Adviser's ABBV Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its AbbVie (ABBV) stake by 10% in Q2 2026, selling an estimated $477K and leaving 19,587 shares worth $4.93M. The position accounts for 2.04% of the portfolio, ranked #9.

DoubleLine ETF Adviser first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

DoubleLine ETF Adviser held 19,587 shares of AbbVie worth $4.93M as of Q2 2026.
DoubleLine ETF Adviser sold 2,217 AbbVie shares in Q2 2026, an estimated $477K.
AbbVie made up 2.04% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #9 holding.
DoubleLine ETF Adviser first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.